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Abstract 
Background. Generic omeprazole contains the same active ingredient as original 
omeprazole and require verification of the bioequivalence with original omeprazole. 
However, very few clinical studies have been reported. 
Aims. A prospective, randomized, open-label, crossover study to compare 
acid-suppressive effect of generic omeprazole with that of original omeprazole. 
Subjects. Seven healthy Helicobacter pylori-negative subjects of CYP2C19 extensive 
metabolizer. 
Methods. Intragastric pH was measured for 24-h without medications (placebo) and on 
day 7 of repeated administration of 10 mg once daily after breakfast of original 
omeprazole, Omeprazon, or three brands of generic omeprazole, Omeprazole-Towa, 
Ovulanze or Omerap. 
Results. Median values of intragastric pH and percentages of time with pH > 4 for 24-h 
were significantly higher with administration of any omeprazole formulation compared 
with placebo (P < 0.05, Wilcoxon signed-rank test). Whereas, during the night-time 
period (20:00-08:00 h), percentages of time with pH > 4 with Omeprazole-Towa and 
Omerap were not significantly higher than placebo. Compared with Omeprazon, these 
two parameters for 24-h showed significantly greater inter-subject variations with 
Omeprazole-Towa (P < 0.05 and P < 0.01, F-test) and Ovulanze (P < 0.05). 
Conclusions. Acid-suppressive effects of some brands of generic omeprazole are not 
the same as original omeprazole. These differences might be reflected in clinical 
outcomes. 
Keywords: Generic product, Intragastric pH, Omeprazole 
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1. Introduction 
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole and rabeprazole, 
are considered to have stronger gastric acid-suppressive effects than histamine H2 
receptor antagonists [1–4], and are widely used in initial and maintenance therapy for 
gastroesophageal reflux disease (GERD). 
Recently, it has been found that cytochrome P450 2C19 (CYP2C19), which is a 
major enzyme involved in PPI metabolism [5], has three hereditary genotypes: 
homozygous extensive metabolizers with higher enzymatic activity, heterozygous 
extensive metabolizers with moderate enzymatic activity, and poor metabolizers with 
markedly impaired enzyme activity [6–9]. Therefore, a subject's CYP2C19 genotype 
affects the acid-suppressive effects of PPIs, and differences in its effects among the 
three genotypic groups are significant [10–15]. As a result, the acid-suppressive effect 
of PPIs should be studied in relation to CYP2C19 genotype status. 
   In Japan, as well as many other countries, in an effort to reduce medical expenditure, 
the authorities have recently been promoting the use of generic drugs which contain the 
same active ingredients as the original products, and this may involve verifying the 
stability, quality and effects of the generic drugs. However, in terms of volume of all 
prescriptions, generic products accounted for only 11% in Japan, but 54% in the United 
States, 52% in the United Kingdom, and 54% in Germany in 2001 [16].  
Since 2004, an increasing number of generic omeprazole-containing products have 
been on the market in Japan. Studies to determine the bioequivalence between original 
and generic omeprazole have been performed [17-19], however, most of them did not 
take account of CYP2C19 genotypic status [18, 19]. Therefore, it is difficult to assess 
whether each generic omeprazole formulation exhibits exactly the same pattern of drug 
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absorption as original omeprazole. Moreover, questions of therapeutic equivalence can 
also be raised. 
The aim of this study was to compare the acid-suppressive effects of 10 mg of three 
brands of generic omeprazole recently available in Japan, as test products, with original 
omeprazole, as a reference product, in CYP2C19 extensive metabolizers without 
Helicobacter pylori (H. pylori) infection. 
 
2. Materials and methods 
2.1. Subjects 
Seven healthy Japanese subjects (six males and one female) who were H. 
pylori-negative CYP2C19 extensive metabolizers (five homozygous extensive 
metabolizers and two heterozygous extensive metabolizers) participated in this study. 
The subjects, aged 22–33 years (median 24 years) and weighing 55–95 kg (median 67 
kg), had no history of gastrointestinal or hepatobiliary disease, or of eradication therapy 
for H. pylori, and took no regular medications. The full medical history of each subject 
was recorded and each received a physical examination. 
 
2.2. H. pylori infection 
H. pylori infection was determined by measuring the serum titer of IgG antibodies 
to H. pylori by an enzyme immunoassay (HM-CAP Kit, Enteric Products, NY, USA), 
and by the 13C-urea breath test (UBT). Only subjects negative to both tests were 
considered to be free from H. pylori infection.  
 
2.3. CYP2C19 genotyping 
 4 
Genotyping procedures identifying the CYP2C19*1 wild-type gene and the two 
mutated alleles, CYP2C19*2 in exon 5 and CYP2C19*3 in exon 4, were performed by a 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
method, originally described by de Morais et al. [20, 21], with minor modifications as 
reported by Kubota et al. [8], at the laboratory center at SRL, Tokyo, Japan. Genotypic 
status was determined by the existence of CYP2C19*2 in exon 5 and/or CYP2C19*3 in 
exon 4: homozygous extensive metabolizers, *1/*1; heterozygous extensive 
metabolizers, *1/*2 and *1/*3. 
 
2.4. 24-h intragastric pH monitoring 
Before each recording session, a glass electrode (CM-181, Chemical Instruments, 
Tokyo, Japan) was calibrated in buffer solutions at pH 6.86 and 4.01. At 16:00 h, the pH 
electrode was inserted through the nose and the tip was fluoroscopically positioned in 
the upper portion of the gastric corpus (10 cm below the gastroesophageal junction) and 
connected to a portable digital recorder (CR-5501 or PH-101Z, Chemical Instruments, 
Tokyo, Japan). At 17:00 h, measurement of intragastric pH was started and continued 
for 24-h. At fixed times (dinner at 18:00 h, breakfast at 08:00 h, and lunch at 12:00 h), 
standardized meals were taken (total calories = 1900 kcal/day: protein 70 g, lipids 50 g, 
carbohydrate 290 g). Subjects were free to drink water during the 24-h period, but were 
not allowed to smoke though other normal daily activities were not restricted.  
 
2.5. Study protocol 
This was a prospective, randomized, open-label, five-way, crossover study. 10 mg 
tablets of original omeprazole, Omeprazon (Mitsubishi Pharma, Osaka, Japan, 
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collaboration with AstraZeneca, London, UK, Lot No. L071), and three brands of 
generic omeprazole, Omeprazole-Towa (Towa Pharmaceuticals, Osaka, Japan, Lot No. 
C306), Ovulanze (Taiyo Yakuhin, Aichi, Japan, Lot No. 325901) and Omerap 
(Nichi-iko Pharmaceuticals, Toyama, Japan, Lot No. EP2401) were purchased on the 
market in December 2004. Results of previous bioavailability/bioequivalence studies 
between original and generic omeprazole are shown in Table 1 [17-19]. Then, in a 
randomized order, each subject was repeatedly administered once daily after breakfast 
either of the four drugs or placebo for 7 consecutive days. Intragastric pH was measured 
for 24-h five times; on day 7 of each period of repeated administration of the four drugs 
or placebo. Between each period of administration there was a wash-out period of 2 
weeks or more. 
   This study was conducted in accordance with the Declaration of Helsinki and 
Ethical Guideline on Human Genome and Genetic Analyses in Japan, and approved by 
the Ethical Committee of Hiroshima University Hospital. Written informed consent was 
obtained from all subjects prior to study entry. 
 
2.6. Data analysis  
After the 24-h monitoring of intragastric pH, the recorded values were transferred to 
a personal computer for processing and analysis using a commercially available 
software program (Chemical Instruments, Tokyo, Japan). The median value of 
intragastric pH and the percentage of time that intragastric pH was above 4 were 
calculated. These parameters are widely used and represent the degree of gastric acid 
suppression. 
   Nocturnal gastric acid breakthrough (NAB) was defined as at least 60 continuous 
 6 
minutes of intragastric pH below 4 during the midnight-time period (22:00-06:00 h) 
[22]. 
 
2.7. Statistical analysis 
The parameters were expressed as median values with ranges. Differences in median 
value of intragastric pH and the percentage of time that intragastric pH was above 4 
between placebo and each omeprazole formulation were determined by the Wilcoxon 
signed-rank test. Differences in inter-subject variations of these parameters between 
original omeprazole and generic omeprazole were compared by the F-test. A P value 
less than 0.05 was considered statistically significant. 
 
3. Results 
3.1. Intragastric pH profiles 
The 24-h intragastric pH (median pH per hour) profiles without medication 
(placebo) and on day 7 of repeated administration of 10 mg once daily original 
omeprazole, Omeprazon, or three brands of generic omeprazole, Omeprazole-Towa, 
Ovulanze or Omerap, are shown in Fig. 1. Median values of intragastric pH increased 
above 4 for 2-h or more after dinner and lunch during administration of both original 
omeprazole and the three brands of generic omeprazole, compared with the 
placebo-controlled data. At night time, intragastric pH values continuously increased to 
approximately 4 with Omeprazon and Ovulanze, however, they only reached about 3 
with Omeprazole-Towa and Omerap. 
 
3.2. Median values of intragastric pH 
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Box-whisker plots of the median values of 24-h intragastric pH without medication 
(placebo) and on day 7 of repeated administration once daily after breakfast of 10 mg 
Omeprazon, Omeprazole-Towa, Ovulanze or Omerap are shown in Fig 2. Compared 
with the placebo-controlled data [1.7 (1.6–2.4)], the median values of 24-h intragastric 
pH increased significantly with both original and generic omeprazole; Omeprazon [2.4 
(2.1–3.3), P < 0.05], Omeprazole-Towa [2.5 (1.7–4.3), P < 0.05], Ovulanze [2.7 
(1.7–4.7), P < 0.05] and Omerap [2.5 (2.3–3.2), P < 0.05]. 
Compared with Omeprazon, significantly larger range of inter-subject variation was 
observed in median values of 24-h intragastric pH with Omeprazole-Towa and 
Ovulanze (P < 0.05). 
 
3.3. Percentages of time that intragastric pH was above 4 
Box-whisker plots of the percentages of time that intragastric pH was above 4 
without medication (placebo) and on day 7 of repeated administration once daily after 
breakfast of 10 mg Omeprazon, Omeprazole-Towa, Ovulanze or Omerap are shown in 
Fig. 3A and B. Compared with the placebo-controlled data [5% (3–14%)], the 
percentages of time that intragastric pH was above 4 during 24-h increased significantly 
with original and generic omeprazole [26% (11–41%) with Omeprazon (P < 0.05), 16% 
(5–58%) with Omeprazole-Towa (P < 0.05), 29% (11–54%) with Ovulanze (P < 0.05), 
and 23% (12–43%) with Omerap (P < 0.05), respectively]. Compared with Omeprazon, 
significantly larger range of inter-subject variation was observed in this parameter 
during 24-h with Omeprazole-Towa (P < 0.01) and Ovulanze (P < 0.05). On the other 
hand, during the night-time period (20:00-08:00 h), this parameter also increased 
significantly with Omeprazon [16% (7–41%) (P < 0.05)] and Ovulanze [28% (4–52%) 
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(P < 0.05)], compared with the placebo-controlled data [3% (0–18%)], whereas this 
parameter did not increase significantly with Omeprazole-Towa [8% (0–43%) and 
Omerap [12% (3–29%)]. 
 
3.4. Nocturnal gastric acid breakthrough (NAB) 
All subjects experienced NAB on day 7 of repeated administration once daily after 
breakfast of 10 mg Omeprazon, Omeprazole-Towa, Ovulanze or Omerap. However, 
compared with the placebo-controlled data, the duration of NAB was significantly 
reduced during either of original or generic omeprazole (P < 0.05) (Table 2). 
 
4. Discussion 
This study revealed that the acid-suppressive effects of some brands of generic 
omeprazole were insufficient, moreover, significantly larger range of inter-subject 
variation in the effect was observed with some generic omeprazole formulations. 
In this study, omeprazole was administered at a low dose, i.e. 10 mg once daily after 
breakfast, in H. pylori-negative CYP2C19 extensive metabolizers, because most GERD 
patients, who need long-term maintenance therapy with omeprazole, are without H. 
pylori infection [23, 24]. Furthermore, the inter-subject variation of the acid-suppressive 
effect is smaller in subjects without H. pylori infection than in those with such infection 
[25, 26], and in CYP2C19 extensive metabolizers the acid-suppressive effect of 
omeprazole 10 mg once daily is not as potent as 20 mg [14]. Therefore, we considered 
that differences in the acid-suppressive effect would be more clearly revealed among the 
original and generic omeprazole. In addition, in Japan omeprazole 40 mg is not 
approved for use as initial therapy for acid-related diseases, only 20 mg or less is 
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permitted. Furthermore, 10 mg is the dose of omeprazole most often used for 
maintenance therapy for GERD in Japan. 
In Japan, omeprazole is usually administered after breakfast, whereas in many other 
countries it is administered before breakfast. The bioavailability of omeprazole is 
thought to be influenced by concomitant food intake. However, no significant difference 
was observed in the acid-suppressive effect of single oral administration of omeprazole 
20 mg between before breakfast and after breakfast [27], as well as in the area under the 
concentration-time curve (AUC) of omeprazole after single oral administration of 
omeprazole 20 mg between before breakfast and after breakfast [28, 29]. From this 
background, we consider that the results of this study are not different from that if 
omeprazole had been administered before breakfast. 
An original product is the first to appear on the market and is patent-protected. In 
Japan, patents give exclusive production rights for 20–25 years following application. 
However, with patent expiry other manufacturers can produce and market generic 
versions of original drugs, which contain the same active ingredients, and this involves 
verification of the stability, quality and effect (i.e., bioequivalence) of the new product 
[30]. In general, however, no studies have been required for generic products when they 
are compared on clinical grounds, e.g., therapeutic or adverse effects, with their original 
products. 
According to previous reports and information provided by each drug manufacturer, 
there are no significant differences in pharmacokinetic parameters after single oral 
administration of 10 mg original omeprazole or the three brands of generic omeprazole 
(Table 1). The effective ingredient of any generic omeprazole is exactly the same as 
original omeprazole, therefore, it is likely that the reduced acid-suppression and larger 
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range of inter-subject variation of generic omeprazole results from greater inter-subject 
variation in the process of intestinal absorption, rather than variation in systemic 
clearance.  
Omeprazole has low water solubility and is degraded by gastric acid, therefore, an 
acid-resistant formulation of omeprazole, consisting of enteric-coated granules, has been 
developed for oral use to minimize degradation in the stomach. Previously, stability of 
each omeprazole formulation, i.e., its dissolution and release, has been tested [31–36], 
and in some cases bioequivalence could not be proven [31, 35, 36]. Concerning the 
results of our study, different performance of the granule coating between original and 
generic omeprazole may be a major determinant of reduced acid-suppression and 
greater inter-subject variation. 
The end-point of this comparative study should be the therapeutic outcomes; 
because significantly larger range of inter-subject variation of the acid-suppressive 
effects of generic omeprazole does not necessarily imply therapeutic inequivalence. No 
significant difference was observed between original and generic omeprazole available 
in Israel, Omepradex, as part of PPI-based triple therapy for eradication of H. pylori 
[37], although Cmax and AUC differed significantly between these two formulations 
after repeated administration [35]. Further clinical comparisons are needed. 
 
5. Conclusion 
This prospective study has demonstrated that the acid-suppressive effects of 
repeated administration of 10 mg once daily after breakfast of three brands of generic 
omeprazole, Omeprazole-Towa, Ovulanze and Omerap, were not the same as that of 
original omeprazole, Omeprazon: During the night-time period, the percentages of time 
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that intragastric pH was above 4 were not significantly higher with Omeprazole-Towa 
and Omerap than the placebo-controlled data. Moreover, with Omeprazole-Towa and 
Ovulanze, there were significantly larger range of inter-subject variations in the median 
values of intragastric pH and the percentages of time that intragastric pH was above 4 
for 24-h, compared with Omeprazon. 
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Figure legends 
Fig 1. 24-h intragastric pH (median pH per hour) profiles without medication (placebo) 
and on day 7 of repeated administration once daily after breakfast of 10 mg original 
omeprazole, Omeprazon, or three brands of generic omeprazole, Omeprazole-Towa, 
Ovulanze or Omerap in H. pylori-negative CYP2C19 extensive metabolizers. (D, 
dinner; B, breakfast; L, lunch.) 
 
Fig 2. Box-whisker plots of the median values of 24-h intragastric pH without 
medication (placebo) and on day 7 of repeated administration once daily after breakfast 
of 10 mg original omeprazole, Omeprazon, or three brands of generic omeprazole, 
Omeprazole-Towa, Ovulanze or Omerap in H. pylori-negative CYP2C19 extensive 
metabolizers. (*P < 0.05 vs. placebo-controlled data by the Wilcoxon signed-rank test; 
#P < 0.05 between original omeprazole and generic omeprazole by the F-test.) 
 
Fig 3. Box-whisker plots of the percentages of time that intragastric pH was above 4 
during the 24-h (A) and night-time period (20:00-08:00 h) (B) without medication 
(placebo) and on day 7 of repeated administration once daily after breakfast of 10 mg 
original omeprazole, Omeprazon, or three brands of generic omeprazole, 
Omeprazole-Towa, Ovulanze or Omerap in H. pylori-negative CYP2C19 extensive 
metabolizers. (*P < 0.05 vs. placebo-controlled data by the Wilcoxon signed-rank test; 
#P < 0.05 and ##P < 0.01 between original omeprazole and generic omeprazole by the 
F-test.) 
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Fig. 1 
 
Fig. 2 
 
 
Fig.3 
 
Table 1. Results of bioavailability/bioequivalence studies of single oral administration of 10 mg tablet of original omeprazole and three 
brands of generic omeprazole, Omeprazole-Towa, Ovulanze and Omerap [17-19]. 
 Subject no. Cmax (ng/ml) tmax (h) AUC (ng･h/ml) t1/2 (h) Ref. no. 
Omepral* 
Omeprazole-Towa 
 
Omeprazon 
Ovulanze 
 
Omepral*,*** 
Omerap*** 
22** 
22** 
 
29 
29 
 
20 
20 
179.78 ± 107.81 
183.70 ± 135.43 
 
279.0 ± 182.6 
266.9 ± 169.6 
 
471.3 ± 314.1 
429.2 ± 289.0 
1.95 ± 0.77 
1.52 ± 0.76 
 
1.8 ± 0.8 
1.8 ± 1.0 
 
1.85 ± 0.86 
1.88 ± 0.93 
199.61 ± 113.13 
206.40 ± 129.16 
 
559.1 ± 623.9 
537.6 ± 584.5 
 
1165.5 ± 1452.1 
1091.8 ± 1318.5 
0.6251 ± 0.2470 
0.7864 ± 0.4893 
 
1.57 ± 1.58 
1.25 ± 0.68 
 
1.40 ± 1.13 
1.48 ± 0.80 
 
17 
 
 
18 
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Results were expressed as means ± S.D. *Omepral, another original omeprazole available in Japan, AstraZeneca, Osaka, Japan. 
**Cross-over comparative study in CYP2C19 homozygous extensive metabolizers. ***Cross-over comparative study between 20 mg 
(two 10 mg tablets) Omepral and 20 mg (two 10 mg tablets) Omerap.  
 Table 2. Incidence and duration of nocturnal gastric acid breakthrough (NAB) without medication (placebo) and on day 7 of repeated 
administration once daily after breakfast of 10 mg original omeprazole, Omeprazon, or three brands of generic omeprazole, 
Omeprazole-Towa, Ovulanze or Omerap, in Helicobacter pylori-negative CYP2C19 extensive metabolizers. 
 Control Omeprazon Omeprazole-Towa Ovulanze Omerap 
NAB 
Incidence 
Duration 
 
7/7 (100%) 
480min (285-480min)
 
7/7 (100%) 
242min (238-350min)*
 
7/7 (100%) 
254min (181-480min)*
 
7/7 (100%) 
283min (73-387min)*
 
7/7 (100%) 
308min (172-480min)*
Parameters were expressed as median values with ranges. *P < 0.05 vs. placebo-controlled data by the Wilcoxon signed-rank test. 
Incidence, incidence of NAB; Duration, duration of NAB. 
 
